---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-059117"
form_type: "8-K"
ticker: "BGMS"
cik: "0001130166"
company_name: "Bio Green Med Solution, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T03:34:02.374179+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cyclacel Q1 net loss $5.8M; non-dilutive $4.7M tax credit bolsters cash into Q1 2024

## Summary
- Net loss $5.8M in Q1 2023 vs $4.1M year ago; cash $11.4M plus $4.7M R&D tax credit received.
- R&D expenses $5.7M, up 14% YoY, with fadraciclib costs $4.1M and plogosertib $1.4M.
- Expects Phase 1/2 data for oral fadraciclib and plogosertib in 2023; Phase 2 PoC enrollment ready.
- Cash runway estimated into Q1 2024; royalty income declined $1.1M YoY.

## SEC filing metadata
- accession: 0001104659-23-059117
- form_type: 8-K
- ticker: BGMS
- cik: 0001130166
- company_name: Bio Green Med Solution, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130166/000110465923059117/0001104659-23-059117-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130166/000110465923059117/tm2315482d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-059117
- JSON: https://secwatch.observer/filing/0001104659-23-059117.json
- Plain text: https://secwatch.observer/filing/0001104659-23-059117.txt

## Key facts
- Earnings Releases
  Bio Green Med Solution, Inc. reported first quarter ended March 31, 2023 results: net income Net loss for the three months ended March 31, 2023, was $5.8 million.
  - Period: first quarter ended March 31, 2023
  - Net income: Net loss for the three months ended March 31, 2023, was $5.8 million
  - Result: reported results
  source text: Net loss for the three months ended March 31, 2023, was $5.8 million, compared to $4.1 million for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1130166/000110465923059117/0001104659-23-059117-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.